Access to Innovative Therapies Streamlined
The Innovative Licensing and Access Pathway (ILAP) in the UK provides a unique framework for developers, facilitating coordinated support throughout the development process. This comprehensive pathway enables collaboration between developers and key stakeholders—including the national health system, regulators, and health technology assessment bodies—right from the early stages of clinical development.
ILAP aims to mitigate risks associated with product development and fast-track patient access to revolutionary new medicines and drug-device combinations, offering a single integrated platform for collaboration.
Recent Recipients of Innovation Passports
Following a thorough evaluation by the ILAP Selection Panel, several therapies have recently been awarded Innovation Passports:
- A small interfering RNA (siRNA) aimed at treating Huntington’s disease.
- A novel small molecule oncology treatment targeting first-line therapy for Non-Small Cell Lung Cancer (NSCLC).
- An Antisense Oligonucleotide (ASO) developed for early-stage Alzheimer’s disease.
Huntington’s disease, a rare inherited neurodegenerative condition, imposes a significant burden on both patients and their families. NSCLC, which represents approximately 80–85% of lung cancer cases, sees around 50,200 diagnoses annually in the UK. Meanwhile, Alzheimer’s disease, the most prevalent cause of dementia, affects an estimated 982,000 individuals in the UK, a number that is projected to rise.
Expert Insights on the ILAP’s Impact
Professor Jacob George, Chief Medical and Scientific Officer of the Medicines and Healthcare products Regulatory Agency, highlighted the ILAP as a groundbreaking initiative designed to expedite patient access to innovative therapies. He remarked on the issuance of Innovation Passports to three promising therapies that could address significant unmet needs in the realms of Alzheimer’s, lung cancer, and Huntington’s disease.
John Spoors, Deputy Director of Medicines Evaluation at NICE, expressed enthusiasm over the granting of Innovation Passports, emphasising the potential for collaborative efforts with developers to foster evidence generation and early engagement on critical issues that will influence future evaluations and patient access.
Commitment to Addressing Unmet Medical Needs
Dr Rob Peel, chair of the Scottish Medicines Consortium, conveyed support for the ILAP’s initiative in recognising new therapies for Huntington’s disease, Alzheimer’s disease, and lung cancer. He noted the substantial impact these conditions have on patients and healthcare systems, emphasising the importance of innovation in meeting these urgent health needs.
Dr Andrew Champion, Programme Director at AWTTC, shared optimism regarding the Innovation Passports awarded to these investigational treatments. He affirmed the commitment to collaborate with UK partners to ensure that patient needs are central to the development and assessment processes.
Industry Leaders Acknowledge the Need for New Treatments
Yvonne Greenstreet, CEO of Alnylam, addressed the critical need for effective therapies to slow the progression of Huntington’s disease, expressing gratitude for the Innovation Passport awarded to their investigational RNAi therapeutic, brezosiran. She looks forward to collaborating with MHRA and ILAP partners to expedite its development.
Similarly, James Harris, Interim General Manager of BeOne Medicines UK & Ireland Ltd., pointed out the persistent unmet needs in NSCLC treatment, particularly for patients with MTAP-deficient tumours. The Innovation Passport for BGB-58067 represents a significant step in addressing these gaps in therapy.
Dr Kylie Bromley, Managing Director of Biogen UK & Ireland, welcomed the Innovation Passport designation for diranersen, highlighting the opportunity for collaborative efforts to ensure that innovations reach the patients who require them most.
Future Development and Application Process
It is important to note that the products awarded Innovation Passports are still in the development phase, and their future availability will hinge on demonstrating safety, efficacy, and value.
Developers of innovative medicines addressing unmet patient needs across various therapeutic areas are encouraged to consider the eligibility criteria and submit their applications. The next round of Innovation Passports is now open, with applications accepted until 11 February 2027.
Collaborative Partnership for Enhanced Health Outcomes
The ILAP is a collaborative initiative involving the Medicines and Healthcare products Regulatory Agency, NHS England, and various Health Technology Assessment bodies, including NICE, the Scottish Medicines Consortium, and the All Wales Therapeutics and Toxicology Centre, along with the Department of Health in Northern Ireland.
This initiative is open to both commercial and non-commercial developers globally, inviting submissions for medicines or drug-device combinations that have yet to enter confirmatory trials. This approach allows for maximising the potential benefits of the support offered within the pathway.
The MHRA, as an executive agency of the Department of Health and Social Care, is committed to ensuring the safety and efficacy of all medicines and medical devices in the UK, informing its decision-making through robust, evidence-based assessments.